Collegium Pharmaceutical Inc (COLL) 2024年CSR报告「NASDAQ」.pdf

1、ESG Report 2024Table of ContentsCEO Message 32024 ESG Highlights 4ESG at Collegium 5About Collegium 6Governance 11Social 14Environment 24Further Resources 26Forward-Looking Statements 26ESG Report 20242When I joined Collegium in November 2024 as President and Chief Executive Officer,I was deeply imp

2、ressed by our talented teams dedication to improving the lives of people living with serious medical conditions.Our commitment to leading with science ensures that our portfolio provides effective treatment options for patients,while also supporting the healthcare providers who care for them.The man

3、y accomplishments highlighted in this report stand as a testament to our dedication and passion in service of our mission.These efforts continuously uphold the highest standards of corporate responsibility and integrity in our industry.2024 was a transformative year.We solidified our leadership in r

4、esponsible pain management and expanded into neuropsychiatry through the acquisition of Ironshore Therapeutics and its product,Jornay PM,which is a highly differentiated medicine for the treatment of attention deficit hyperactivity disorder(ADHD)and is poised to be our lead growth driver.We are prou

5、d of our meaningful and differentiated medicines,as well as our ability to generate shareholder value.Beyond achieving our business objectives,2024 was also a year marked by positive impact CEO MessageVikram Karnani President and Chief Executive Officer on our communities.We drove meaningful change

6、through our commitment to Do Good as We Do Well.This responsibility goes beyond our business goals it extends to shaping the next generation of life science leaders,supporting our neighbors in need and doing our part to protect our planet for future generations.Through our culture of service and com